Doddareddy Munikumar Reddy, Choo Hyunah, Cho Yong Seo, Rhim Hyewhon, Koh Hun Yeong, Lee Jung-Ha, Jeong Seong-Woo, Pae Ae Nim
Life Science Division, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea.
Bioorg Med Chem. 2007 Jan 15;15(2):1091-105. doi: 10.1016/j.bmc.2006.10.013. Epub 2006 Oct 30.
Virtual screening of the commercial databases was done by using a three dimensional pharmacophore previously developed for T-type calcium channel blockers using CATALYSTtrade mark program. Biological evaluation of 25 selected virtual hits resulted in the discovery of a highly potent compound VH04 with IC(50) value of 0.10 microM, eight times as potent as the known selective T-type calcium channel blocker, mibefradil. Search for similar compounds yielded several hits with micro-molar IC(50) values and high T-type calcium channel selectivity. Based on the structure of the virtual hits, small molecule libraries with novel scaffolds were designed, synthesis and biological evaluation of which are currently in progress. This result shows a successful example of ligand based drug discovery of potent T-type calcium channel blockers.
利用先前使用CATALYST商标程序为T型钙通道阻滞剂开发的三维药效团,对商业数据库进行虚拟筛选。对25种选定的虚拟命中化合物进行生物学评估,发现了一种高效化合物VH04,其IC(50)值为0.10微摩尔,效力是已知选择性T型钙通道阻滞剂米贝拉地尔的8倍。搜索类似化合物得到了几个IC(50)值为微摩尔级且具有高T型钙通道选择性的命中化合物。基于虚拟命中化合物的结构,设计了具有新型骨架的小分子文库,目前正在进行其合成和生物学评估。这一结果展示了基于配体的强效T型钙通道阻滞剂药物发现的成功范例。